Singapore markets closed

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1840+0.0030 (+1.66%)
At close: 04:00PM EDT
0.1825 -0.00 (-0.82%)
Pre-market: 06:41AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1810
Open0.1786
Bid0.1853 x 1600
Ask0.1857 x 3200
Day's range0.1632 - 0.1963
52-week range0.0810 - 5.6000
Volume9,304,029
Avg. volume13,889,682
Market cap10.176M
Beta (5Y monthly)0.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

    Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.

  • PR Newswire

    Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

    Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and res

  • PR Newswire

    Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

    Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.